AU2008250945B2 - Bone targeted alkaline phosphatase, kits and methods of use thereof - Google Patents

Bone targeted alkaline phosphatase, kits and methods of use thereof Download PDF

Info

Publication number
AU2008250945B2
AU2008250945B2 AU2008250945A AU2008250945A AU2008250945B2 AU 2008250945 B2 AU2008250945 B2 AU 2008250945B2 AU 2008250945 A AU2008250945 A AU 2008250945A AU 2008250945 A AU2008250945 A AU 2008250945A AU 2008250945 B2 AU2008250945 B2 AU 2008250945B2
Authority
AU
Australia
Prior art keywords
alkaline phosphatase
amino acid
sequence
residue
signal peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
AU2008250945A
Other languages
English (en)
Other versions
AU2008250945A2 (en
AU2008250945A1 (en
Inventor
Guy Boileau
Philippe Crine
Robert Heft
Hal Landy
Isabelle Lemire
Pierre Leonard
Thomas P. Loisel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alexion Pharmaceuticals Inc
Original Assignee
Alexion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharmaceuticals Inc filed Critical Alexion Pharmaceuticals Inc
Publication of AU2008250945A1 publication Critical patent/AU2008250945A1/en
Publication of AU2008250945A2 publication Critical patent/AU2008250945A2/en
Assigned to ENOBIA CANADA LIMITED PARTNERSHIP reassignment ENOBIA CANADA LIMITED PARTNERSHIP Request for Assignment Assignors: ENOBIA PHARMA INC.
Assigned to ALEXION PHARMA INTERNATIONAL SARL reassignment ALEXION PHARMA INTERNATIONAL SARL Request for Assignment Assignors: ENOBIA CANADA LIMITED PARTNERSHIP
Priority to AU2013203875A priority Critical patent/AU2013203875A1/en
Assigned to ALEXION PHARMA HOLDING reassignment ALEXION PHARMA HOLDING Request for Assignment Assignors: ALEXION PHARMA INTERNATIONAL SARL
Application granted granted Critical
Publication of AU2008250945B2 publication Critical patent/AU2008250945B2/en
Assigned to ALEXION PHARMACEUTICALS, INC. reassignment ALEXION PHARMACEUTICALS, INC. Request for Assignment Assignors: ALEXION PHARMA HOLDING
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03001—Alkaline phosphatase (3.1.3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cereal-Derived Products (AREA)
  • Adornments (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
AU2008250945A 2007-05-11 2008-05-12 Bone targeted alkaline phosphatase, kits and methods of use thereof Active 2031-01-14 AU2008250945B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2013203875A AU2013203875A1 (en) 2007-05-11 2013-04-11 Bone Targeted Alkaline Phosphatase, Kits and Methods of Use Thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91758907P 2007-05-11 2007-05-11
US60/917,589 2007-05-11
PCT/CA2008/000923 WO2008138131A1 (en) 2007-05-11 2008-05-12 Bone targeted alkaline phosphatase, kits and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2013203875A Division AU2013203875A1 (en) 2007-05-11 2013-04-11 Bone Targeted Alkaline Phosphatase, Kits and Methods of Use Thereof

Publications (3)

Publication Number Publication Date
AU2008250945A1 AU2008250945A1 (en) 2008-11-20
AU2008250945A2 AU2008250945A2 (en) 2009-12-24
AU2008250945B2 true AU2008250945B2 (en) 2013-12-12

Family

ID=40001639

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008250945A Active 2031-01-14 AU2008250945B2 (en) 2007-05-11 2008-05-12 Bone targeted alkaline phosphatase, kits and methods of use thereof

Country Status (25)

Country Link
US (1) US20100297119A1 (cg-RX-API-DMAC7.html)
EP (3) EP2158319B1 (cg-RX-API-DMAC7.html)
JP (1) JP5732603B2 (cg-RX-API-DMAC7.html)
AT (1) ATE536413T1 (cg-RX-API-DMAC7.html)
AU (1) AU2008250945B2 (cg-RX-API-DMAC7.html)
BR (2) BRPI0811198B8 (cg-RX-API-DMAC7.html)
CA (1) CA2687001C (cg-RX-API-DMAC7.html)
CY (1) CY2016005I2 (cg-RX-API-DMAC7.html)
DE (1) DE202008018131U1 (cg-RX-API-DMAC7.html)
DK (3) DK2368999T3 (cg-RX-API-DMAC7.html)
ES (3) ES2619332T3 (cg-RX-API-DMAC7.html)
FR (1) FR16C0007I2 (cg-RX-API-DMAC7.html)
HR (1) HRP20140416T1 (cg-RX-API-DMAC7.html)
HU (2) HUE031655T2 (cg-RX-API-DMAC7.html)
IL (1) IL202057A0 (cg-RX-API-DMAC7.html)
LT (1) LTC2368999I2 (cg-RX-API-DMAC7.html)
LU (1) LU92976I2 (cg-RX-API-DMAC7.html)
ME (1) ME01828B (cg-RX-API-DMAC7.html)
NL (1) NL300798I2 (cg-RX-API-DMAC7.html)
NO (1) NO2016002I2 (cg-RX-API-DMAC7.html)
PL (3) PL2662448T3 (cg-RX-API-DMAC7.html)
PT (3) PT2368999E (cg-RX-API-DMAC7.html)
RS (1) RS53302B (cg-RX-API-DMAC7.html)
SI (2) SI2662448T1 (cg-RX-API-DMAC7.html)
WO (1) WO2008138131A1 (cg-RX-API-DMAC7.html)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3404102B1 (en) 2004-04-21 2021-08-11 Alexion Pharmaceuticals, Inc. Bone delivery conjugates and method of using same to target proteins to bone
US20070081984A1 (en) 2005-10-11 2007-04-12 Shunji Tomatsu Compositions and methods for treating hypophosphatasia
US8784833B2 (en) * 2006-06-27 2014-07-22 Saint Louis University Prenatal enzyme replacement therapy for hypophosphatasia
KR101580937B1 (ko) 2007-06-01 2015-12-31 유니버시티 오브 매릴랜드, 발티모어 면역글로불린 불변영역 Ｆｃ 수용체 결합제
WO2011113027A2 (en) 2010-03-12 2011-09-15 Synageva Biopharma Corp Npp1 fusion proteins
CN103153344A (zh) 2010-04-30 2013-06-12 阿莱克森国际制药有限公司 用于治疗基质矿化障碍的方法、组合物、和试剂盒
DK2598533T3 (en) 2010-07-28 2019-04-23 Gliknik Inc Fusion proteins of natural human protein fragments to create in an orderly fashion multimerized immunoglobulin FC compositions
US9266939B2 (en) 2010-12-27 2016-02-23 Alexion Pharmaceuticals, Inc. Compositions comprising natriuretic peptides and methods of use thereof
CA2852874A1 (en) * 2011-10-19 2013-04-25 Alexion Pharma Holding Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
JP2015527366A (ja) 2012-08-20 2015-09-17 グリックニック インコーポレイテッド 抗原結合および多価ｆｃガンマ受容体結合活性を有する分子
CN106164262B (zh) * 2014-01-24 2020-08-07 安-法玛公司 嵌合型碱性磷酸酶样蛋白
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
EP3226891B1 (en) 2014-12-05 2025-06-25 Alexion Pharmaceuticals, Inc. Treating seizure with recombinant alkaline phosphatase
JP6868561B2 (ja) 2015-01-28 2021-05-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼ欠損を有する被験者を治療する方法
FI3325011T6 (fi) 2015-07-24 2023-05-11 Ihmisen proteiinifragmenttien fuusioproteiineja järjestyksenmukaisesti multimerisoitujen, paremmin komplementtia sitovien immunoglobuliini-fc-koostumusten muodostamiseksi
HK1257341A1 (zh) * 2015-08-17 2019-10-18 Alexion Pharmaceuticals, Inc. 硷性磷酸酯的制造
US11229686B2 (en) 2015-09-28 2022-01-25 Alexion Pharmaceuticals, Inc. Reduced frequency dosage regimens for tissue non-specific alkaline phosphatase (TNSALP)-enzyme replacement therapy of hypophosphatasia
US11400140B2 (en) 2015-10-30 2022-08-02 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
EP3426286A4 (en) * 2016-03-08 2019-12-04 Alexion Pharmaceuticals, Inc. PROCESS FOR TREATING HYPOPHOSPHATASIA IN CHILDREN
WO2017173395A1 (en) * 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
WO2017171871A1 (en) * 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
CN109152820A (zh) * 2016-04-01 2019-01-04 阿雷克森制药公司 用碱性磷酸酶治疗肌肉无力
US10988744B2 (en) 2016-06-06 2021-04-27 Alexion Pharmaceuticals, Inc. Method of producing alkaline phosphatase
AU2017279538A1 (en) 2016-06-07 2019-01-03 Gliknik Inc. Cysteine-optimized stradomers
ES2887573T3 (es) 2016-06-27 2021-12-23 Alexion Pharma Inc Métodos para el tratamiento de la hipofosfatasia en niños y adolescentes
EP3500289B1 (en) 2016-08-18 2024-10-09 Alexion Pharmaceuticals, Inc. Asfotase alfa for use in treating tracheobronchomalacia
JP7649624B2 (ja) * 2016-11-30 2025-03-21 パーデュー リサーチ ファウンデーション 副甲状腺ホルモン受容体刺激を介する、骨折をターゲティングした骨再生
WO2018107079A1 (en) 2016-12-09 2018-06-14 Gliknik Inc. Manufacturing optimization of gl-2045, a multimerizing stradomer
IL266988B2 (en) 2016-12-09 2024-11-01 Gliknik Inc Methods of treating inflammatory disorders with multivalent fc compounds
WO2018164995A1 (en) * 2017-03-09 2018-09-13 Alexion Pharmaceuticals, Inc . Glycoprotein manufacturing process
CA3057502A1 (en) * 2017-03-31 2018-10-04 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia (hpp) in adults and adolescents
JP7511469B2 (ja) 2017-09-27 2024-07-05 イノザイム ファーマ， インコーポレイテッド 組換えエクトヌクレオチドピロホスファターゼ／ホスホジエステラーゼ（ｎｐｐ１）を使用して心血管機能を改善し、心血管疾患を処置するための方法。
EP3737750B1 (en) 2018-01-09 2024-06-05 Theriva Biologics, Inc. Alkaline phosphatase agents for treatment of neurodevelopmental disorders
JP7214962B2 (ja) * 2018-01-17 2023-01-31 東ソー株式会社 アルカリホスファターゼ高発現動物細胞
EP3773686B1 (en) 2018-03-20 2023-06-07 Theriva Biologics, Inc. Alkaline phosphatase agents for treatment of radiation disorders
ES3032290T3 (en) 2018-03-20 2025-07-16 Theriva Biologics Inc Intestinal alkaline phosphatase formulations
US11913039B2 (en) 2018-03-30 2024-02-27 Alexion Pharmaceuticals, Inc. Method for producing recombinant alkaline phosphatase
CN110499285A (zh) * 2018-05-17 2019-11-26 西安组织工程与再生医学研究所 Alpl基因在制备预防和/或治疗低碱性磷酸酶症的产品中的应用
WO2019232285A1 (en) 2018-05-30 2019-12-05 Purdue Research Foundation Targeting anabolic drugs for accelerated fracture repair
US12268733B2 (en) 2018-08-10 2025-04-08 Alexion Pharmaceuticals, Inc. Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
CN113993541A (zh) 2019-05-06 2022-01-28 合成生物制品有限公司 基于碱性磷酸酶的肿瘤学治疗
AU2020398898A1 (en) 2019-12-09 2022-07-21 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
EP4084819A1 (en) 2020-01-03 2022-11-09 The United States of America, as represented by the Secretary, Department of Health and Human Services Tnap locally administered for promoting periodontal health
CA3190513A1 (en) * 2020-09-03 2022-03-10 Jeffrey S. Bartlett Soluble alkaline phosphatase constructs and expression vectors including a polynucleotide encoding for soluble alkaline phosphatase constructs
KR102571967B1 (ko) * 2021-01-21 2023-08-30 주식회사 마라나노텍코리아 Alp 측정용 바이오 센서
CN117042791A (zh) 2021-02-12 2023-11-10 阿雷克森制药公司 碱性磷酸酶多肽及其使用方法
WO2024050464A2 (en) * 2022-08-31 2024-03-07 University Of Utah Research Foundation Gja1-20k compositions and methods for mitigating ischemia-reperfusion injury

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005103263A1 (en) * 2004-04-21 2005-11-03 Enobia Pharma Inc. Bone delivery conjugates and method of using same to target proteins to bone

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7008A (en) * 1850-01-08 Improvement in alloys for points of lightning-rods
AU687829B2 (en) 1993-06-24 1998-03-05 Advec, Inc. Adenovirus vectors for gene therapy
HU223733B1 (hu) 1993-10-25 2004-12-28 Canji, Inc. Rekombináns adenovírus vektor és eljárás alkalmazására
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
ES2284545T3 (es) 1999-11-16 2007-11-16 Genzyme Corporation Vectores y transgenes con elementos reguladores para la administracion de genes del higado.
US6808905B2 (en) 2001-05-14 2004-10-26 Cell Genesys, Inc. Lentiviral vectors encoding clotting factors for gene therapy
CA2433479A1 (en) 2002-07-22 2004-01-22 F. Hoffmann-La Roche Ag Conjugate of a tissue non-specific alkaline phosphatase and dextran, process for its production and use thereof
US20070081984A1 (en) 2005-10-11 2007-04-12 Shunji Tomatsu Compositions and methods for treating hypophosphatasia
WO2006002203A2 (en) 2004-06-23 2006-01-05 Genzyme Corporation Methods and compositions for the treatment of polycystic diseases
WO2006039480A2 (en) * 2004-09-29 2006-04-13 The Burnham Institute For Medical Research Tissue non-specific alkaline phosphate (tnap): a therapeutic target for arterial calcification
BRPI0515819A (pt) 2004-12-01 2008-08-05 Genzyme Corp métodos para o fornecimento direcionado de material genético ao fìgado

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005103263A1 (en) * 2004-04-21 2005-11-03 Enobia Pharma Inc. Bone delivery conjugates and method of using same to target proteins to bone

Also Published As

Publication number Publication date
SI2368999T1 (sl) 2014-07-31
DE202008018131U1 (de) 2011-12-30
LTPA2016004I1 (lt) 2016-02-25
IL202057A0 (en) 2011-08-01
CA2687001A1 (en) 2008-11-20
AU2008250945A2 (en) 2009-12-24
EP2158319B1 (en) 2011-12-07
NO2016002I1 (no) 2016-02-02
DK2662448T3 (en) 2017-03-20
BR122019000505A2 (pt) 2021-12-14
ES2471915T3 (es) 2014-06-27
CY2016005I1 (el) 2016-08-31
PL2158319T3 (pl) 2012-05-31
EP2368999B1 (en) 2014-03-12
HK1191372A1 (en) 2014-07-25
PT2158319E (pt) 2012-03-06
EP2158319A1 (en) 2010-03-03
DK2158319T3 (da) 2012-03-19
LTC2368999I2 (lt) 2017-09-25
BRPI0811198B8 (pt) 2021-05-25
NO2016002I2 (no) 2016-02-02
EP2368999A1 (en) 2011-09-28
HK1141047A1 (en) 2010-10-29
CY2016005I2 (el) 2016-08-31
LU92976I2 (en) 2016-04-11
BR122019000505B1 (pt) 2022-01-18
EP2158319A4 (en) 2010-07-21
WO2008138131A1 (en) 2008-11-20
HUS1600005I1 (hu) 2016-02-29
JP2010526543A (ja) 2010-08-05
NL300798I1 (cg-RX-API-DMAC7.html) 2016-03-16
AU2008250945A1 (en) 2008-11-20
PL2158319T4 (pl) 2016-04-29
US20100297119A1 (en) 2010-11-25
BRPI0811198B1 (pt) 2021-03-09
FR16C0007I1 (cg-RX-API-DMAC7.html) 2016-04-15
EP2662448A1 (en) 2013-11-13
HUE031655T2 (hu) 2017-07-28
BRPI0811198A8 (pt) 2018-08-14
ES2619332T3 (es) 2017-06-26
PT2368999E (pt) 2014-05-26
WO2008138131A4 (en) 2008-12-31
PT2662448T (pt) 2017-03-29
RS53302B (sr) 2014-08-29
ES2380546T3 (es) 2012-05-16
ATE536413T1 (de) 2011-12-15
BRPI0811198A2 (pt) 2014-10-21
FR16C0007I2 (fr) 2017-01-27
EP2662448B1 (en) 2016-12-21
HRP20140416T1 (hr) 2014-06-20
HK1162589A1 (en) 2012-08-31
SI2662448T1 (sl) 2017-05-31
NL300798I2 (cg-RX-API-DMAC7.html) 2016-03-16
DK2368999T3 (da) 2014-05-26
PL2368999T3 (pl) 2014-08-29
CA2687001C (en) 2019-02-12
JP5732603B2 (ja) 2015-06-10
PL2662448T3 (pl) 2017-07-31
WO2008138131A9 (en) 2009-08-06
ME01828B (me) 2014-12-20

Similar Documents

Publication Publication Date Title
AU2008250945B2 (en) Bone targeted alkaline phosphatase, kits and methods of use thereof
US11224638B2 (en) Treating seizure with recombinant alkaline phosphatase
US9988620B2 (en) Methods, compositions, and kits for the treatment of matrix mineralization disorders
HK1191372B (en) Bone targeted alkaline phosphatase, kits and methods of use thereof
HK1162589B (en) Bone targeted alkaline phosphatase, kits and methods of use thereof
HK1141047B (en) Bone targeted alkaline phosphatase, kits and methods of use thereof
AU2013203875A1 (en) Bone Targeted Alkaline Phosphatase, Kits and Methods of Use Thereof

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 18 NOV 2009

PC1 Assignment before grant (sect. 113)

Owner name: ENOBIA CANADA LIMITED PARTNERSHIP

Free format text: FORMER APPLICANT(S): ENOBIA PHARMA INC.

PC1 Assignment before grant (sect. 113)

Owner name: ALEXION PHARMA INTERNATIONAL SARL

Free format text: FORMER APPLICANT(S): ENOBIA CANADA LIMITED PARTNERSHIP

PC1 Assignment before grant (sect. 113)

Owner name: ALEXION PHARMA HOLDING

Free format text: FORMER APPLICANT(S): ALEXION PHARMA INTERNATIONAL SARL

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: ALEXION PHARMACEUTICALS, INC.

Free format text: FORMER OWNER WAS: ALEXION PHARMA HOLDING

NC Extension of term for standard patent requested (sect. 70)

Free format text: PRODUCT NAME: STRENSIQ ASFOTASE ALFA RCH

Filing date: 20160114

NDA Extension of term for standard patent accepted (sect.70)

Free format text: PRODUCT NAME: STRENSIQ ASFOTASE ALFA RCH

Filing date: 20160114

NDB Extension of term for standard patent granted (sect.76)

Free format text: PRODUCT NAME: STRENSIQ ASFOTASE ALFA RCH

Filing date: 20160114

Extension date: 20310114